{"product_id":"aura-vrio-analysis","title":"Aura Biosciences, Inc. (AURA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Aura Biosciences, Inc. (AURA) truly built to last? This focused VRIO analysis cuts straight to the chase, distilling its competitive DNA - Value, Rarity, Inimitability, and Organization - into the key finding: \u0026amp;O4\u0026amp;. Read on to see exactly how these elements translate into sustainable market power and what it means for their future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Proprietary Virus-Like Drug Conjugate (VDC) Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Aura Biosciences, Inc. (AURA) and trying to figure out if their Virus-Like Drug Conjugate (VDC) platform is a durable moat or just a promising science project. Honestly, the platform is what makes the company; it’s the engine behind bel-sar (AU-011). The near-term risk is entirely tied to clinical milestones, but the underlying tech has some real structural barriers to entry.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Targeted Efficacy and Organ Preservation\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is clear: highly targeted therapies that aim to preserve organ function by delivering a dual mechanism of action right to the solid tumor. This isn't just about killing cancer cells; it’s about sparking a durable, localized immune response. For early choroidal melanoma, an indication with high unmet need and no approved therapies, bel-sar offers a potential first-line treatment where current standards often lead to severe vision loss. The company is pushing this dual mechanism - cytotoxicity plus immune activation - into bladder cancer too, suggesting broad applicability.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at where the money is going to realize this value:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D Expenses (Q3 2025): \u003cstrong\u003e$22.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 3 CoMpass Trial Enrollment Completion: Guided for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1b\/2 Bladder Cancer Data Expected: \u003cstrong\u003eMid-2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: A Unique Delivery and Activation Profile\u003c\/h3\u003e\n\u003cp\u003eThe specific VDC approach, especially with its demonstrated ability to drive focal anti-tumor immune activation, is quite unique in the current oncology landscape. It’s not just another antibody-drug conjugate (ADC); it’s a virus-like particle designed for precision delivery and immune priming. The data showing bel-sar's potential to convert 'Cold' to 'Hot' tumors supports this rarity - it suggests a novel way to engage the immune system locally. This is what separates it from many platform technologies that are incremental improvements.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barriers Due to Proprietary Construct\u003c\/h3\u003e\n\u003cp\u003eWhile the core concept of targeted delivery is known in pharma, the specific proprietary construct of Aura Biosciences' VDC and its validated application in ocular\/urologic oncology are difficult to copy quickly. You can’t just reverse-engineer this overnight. It requires deep, specialized knowledge in virology, conjugation chemistry, and targeted delivery systems. The company backs this up with a significant IP portfolio, which acts as a tangible barrier. What this estimate hides is the years of preclinical work required to get the construct to this stage.\u003c\/p\u003e\n\u003cp\u003eThe complexity is reflected in their IP status as of late 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (as of Q3 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patent Documents (Apps \u0026amp; Grants)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Approx. Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$343M\u003c\/strong\u003e to \u003cstrong\u003e$400.07M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization: Platform-Centric Structure\u003c\/h3\u003e\n\u003cp\u003eYes, the company is organized around this platform, evidenced by its focus on expanding bel-sar into multiple indications like bladder cancer (NMIBC) and metastases to the choroid. Management, led by CEO Elisabet de los Pinos, Ph.D., is clearly prioritizing clinical execution across these indications. Their financial runway, bolstered by a Q3 2025 follow-on offering of approximately \u003cstrong\u003e$69.9 million\u003c\/strong\u003e, suggests they have the resources to see key readouts through. As of June 30, 2025, their cash position of \u003cstrong\u003e$177.3 million\u003c\/strong\u003e was projected to fund operations into the first half of 2027.\u003c\/p\u003e\n\u003cp\u003eThe organization is lean and focused, which is typical for a clinical-stage biotech, but it means they are highly dependent on the success of this single candidate.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Hinged on Data\u003c\/h3\u003e\n\u003cp\u003eThe advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The platform is strong, but in biotech, the real competitive advantage is only cemented by positive, reproducible Phase 3 data and regulatory approval. A clear win in the Phase 3 CoMpass trial for choroidal melanoma, with topline data due in \u003cstrong\u003eQ4 2027\u003c\/strong\u003e, would be the catalyst to shift this to a sustained advantage. Until then, it’s a high-potential, high-risk asset. If the NMIBC data in mid-2026 is compelling, that could also significantly de-risk the platform's broader applicability.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Phase 3 Registration-Enabling Data for bel-sar in Early Choroidal Melanoma (CoMpass Trial)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This trial is the direct path to the first potential approval for early choroidal melanoma, an area with \u003cstrong\u003eno drugs approved\u003c\/strong\u003e. The global uveal melanoma treatment market is expected to reach \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e by 2033.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. Being the first to run a registration-enabling study under an \u003cstrong\u003eFDA Special Protocol Assessment (SPA)\u003c\/strong\u003e for this rare cancer is rare. Estimated incidence is approximately \u003cstrong\u003e1,500 to 2,000\u003c\/strong\u003e new cases per year in the U.S. and Europe.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No. Competitors cannot easily replicate the trial design or the time already invested in enrolling patients. The trial is a global, Phase 3, randomized trial enrolling approximately \u003cstrong\u003e100 patients\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company implemented measures in \u003cstrong\u003e2025\u003c\/strong\u003e to improve enrollment, showing organizational focus on this critical milestone. As of September 30, 2025, cash and marketable securities totaled \u003cstrong\u003e$161.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Positive data, expected after enrollment completes in \u003cstrong\u003e2026\u003c\/strong\u003e, will lock in a significant market lead.\u003c\/p\u003e\n\u003cp\u003eKey Statistical and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Tumor Control Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmong Phase 3-eligible patients (n=8\/10).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Vision Preservation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn patients responding to treatment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e100\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003ePhase 3 CoMpass trial target.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Completion Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 3 CoMpass trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTopline Data Readout (15-Month Endpoint)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 3 CoMpass trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Marketable Securities (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$161.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance sheet as of Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePhase 2 Efficacy Summary:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTumor growth rate reduced from \u003cstrong\u003e0.351 mm\/year\u003c\/strong\u003e to \u003cstrong\u003e0.011 mm\/year\u003c\/strong\u003e ($\\text{p}\u0026lt;0.0001$) post-treatment.\u003c\/li\u003e\n\u003cli\u003eNo Grade 2 or higher drug-related adverse events reported in safety analysis as of September 9, 2024 ($\\text{n}=12$).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Intellectual Property on Novel bel-sar Formulation for Urologic Oncology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A new formulation for Non-Muscle Invasive Bladder Cancer (NMIBC) is designed for convenient in-office procedures with better handling, potentially boosting adoption if approved.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No. Patent filings are standard, but the specific formulation providing refrigerated storage and ease of use is a specific, valuable asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Yes. Competitors would need to invest significant R\u0026amp;D to develop a functionally equivalent, patent-protected alternative.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The filing shows proactive pipeline management beyond the lead indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Patent protection is strong, but it only becomes sustained if the NMIBC trial yields positive data.\u003c\/p\u003e\n\u003cp\u003eThe intellectual property surrounding the novel bel-sar formulation for urologic oncology is supported by recent clinical and financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMIBC Phase 1 Efficacy (Low Grade)\u003c\/td\u003e\n\u003ctd\u003eClinical Complete Responses (CCR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e out of \u003cstrong\u003e5\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMIBC Phase 1 Immune Activation\u003c\/td\u003e\n\u003ctd\u003eCD4\/CD8 Infiltration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of patients evaluated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMIBC Phase 1 Safety (Drug-Related AEs)\u003c\/td\u003e\n\u003ctd\u003eGrade $\\ge$2 Events\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMIBC Phase 1b\/2 Trial Scope\u003c\/td\u003e\n\u003ctd\u003ePatients to be Evaluated\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e26\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expense (Bel-sar related)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$17.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (As of Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$174.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe proactive management of the bel-sar pipeline for NMIBC is evidenced by the following:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe patent application for the new formulation, if issued, would provide patent coverage into the year \u003cstrong\u003e2046\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe new formulation is specifically designed for enhanced storage and handling at \u003cstrong\u003erefrigerated\u003c\/strong\u003e conditions, specifically \u003cstrong\u003e2-8 Celsius\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe ongoing Phase 1b\/2 trial is designed to evaluate two approaches: an immune ablative design and a multimodal neoadjuvant design.\u003c\/li\u003e\n\u003cli\u003eThe company's cash position as of September 30, 2024, is expected to support operations into the \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2024, were \u003cstrong\u003e\\$17.0 million\u003c\/strong\u003e, compared to \u003cstrong\u003e\\$15.4 million\u003c\/strong\u003e for the same period in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: FDA Fast Track Designation for Metastases to the Choroid Indication\n\u003c\/h2\u003e\n\u003cp\u003eThe following analysis is based on the premise of an FDA Fast Track Designation for the Metastases to the Choroid indication for bel-sar.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePotential acceleration of review process for an indication affecting approximately \u003cstrong\u003e20,000\u003c\/strong\u003e patients annually in the United States and Europe.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eFast Track status is granted to multiple promising candidates.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eRegulatory status granted by the FDA; not a directly imitable asset.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eOrganizational structure supports pursuit of regulatory pathways, evidenced by operational spend.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAccelerates development timeline but does not confer a sustained market exclusivity or commercial success guarantee.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's operational focus and resource allocation support the pursuit of this indication.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2024: \u003cstrong\u003e$17.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the three months ended September 30, 2024: \u003cstrong\u003e$21.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, Cash Equivalents \u0026amp; Marketable Securities as of September 30, 2024: \u003cstrong\u003e$174.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected cash runway into \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAura Biosciences is advancing bel-sar in a planned Phase 2 clinical trial for metastases to the choroid, with sites activated for patient prescreening.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Strong Balance Sheet with Cash Runway into H1 2027\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The cash position, reported at \u003cstrong\u003e$177.3 million\u003c\/strong\u003e as of June 30, 2025, funds operations well into the first half of 2027, reducing immediate dilution risk. The latest reported cash and marketable securities as of September 30, 2025, stood at \u003cstrong\u003e$161.9 million\u003c\/strong\u003e, still sufficient to fund operations into the first half of 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No. Many clinical-stage biotechs have strong cash positions after financing, but this runway is key for near-term stability. The current ratio as of May 2025 was reported at \u003cstrong\u003e10.77\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No. This is a result of past financing events, not an inherent, inimitable capability. The company successfully completed a \u003cstrong\u003e$75 million\u003c\/strong\u003e equity financing in Q2 2025 to bolster this position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company successfully completed a \u003cstrong\u003e$75 million\u003c\/strong\u003e equity financing in Q2 2025 to bolster this position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It buys time, but sustained advantage requires translating that cash into successful trial outcomes.\u003c\/p\u003e\n\u003cp\u003eFinancial Metrics for the Three Months Ended June 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Marketable Securities (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$177.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Financing Proceeds (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional Statistical Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three months ended June 30, 2025, increased from \u003cstrong\u003e$16.9 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses for the three months ended June 30, 2025, decreased from \u003cstrong\u003e$5.9 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ended June 30, 2025, compared to \u003cstrong\u003e$20.3 million\u003c\/strong\u003e for the three months ended June 30, 2024.\u003c\/li\u003e\n\u003cli\u003eStock-based compensation for Q2 2025 was \u003cstrong\u003e$1.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe pivotal Phase 3 CoMpass trial in early choroidal melanoma had over \u003cstrong\u003e240 patients\u003c\/strong\u003e registered for pre-screening as of Q2 2025, with completion targeted by the \u003cstrong\u003eend of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company expects to complete CoMpass enrollment in \u003cstrong\u003e2026\u003c\/strong\u003e and provide topline data readout for the 15-month primary endpoint in the \u003cstrong\u003efourth quarter of 2027\u003c\/strong\u003e (based on Q3 2025 update).\u003c\/li\u003e\n\u003cli\u003eThe Company has a patent application filed for a new formulation of bel-sar for urologic oncology, which if issued, would provide patent coverage into \u003cstrong\u003e2046\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Clinical Data Demonstrating Dual Mechanism of Action (Cytotoxicity + Immunity)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Immune profiling data reinforce bel-sar's unique dual mechanism, suggesting it can convert 'cold' tumors to 'hot' ones, which is a major differentiator. The dual mechanism involves direct tumor cell killing and the deployment of an antitumor-specific immune response, including the activation of $\\text{CD4+}$ and $\\text{CD8+}$ T-cells.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. Showing both direct cell killing and the activation of a broader immune response is a high bar in oncology. Phase 1 trial immune profiling data revealed that a single focal administration of bel-sar induced adaptive immune memory through the generation of de novo mature tertiary lymphoid structures (TLS) in 3\/5 participants evaluated. Bel-sar also generated innate and adaptive effectors regardless of immune environment and converted immune-cold or exhausted lesions into active, immune-hot microenvironments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Replicating the specific immune response profile seen in their Phase 1 data is scientifically challenging. The biological activity profile reinforces bel-sar's potential as a frontline therapy designed to treat the tumor, activate durable anti-tumor immunity, and reduce recurrence risk.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The R\u0026amp;D team is clearly focused on characterizing and communicating this mechanism. The company reported cash and cash equivalents and marketable securities of $187.4 million as of June 30th, 2024, supporting ongoing research and development efforts, including the Phase 1b\/2 trial in $\\text{NMIBC}$ with data expected in mid-2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If this dual mechanism proves superior in Phase 3, it becomes a core, hard-to-replicate asset. Data from the Phase 2 study in choroidal melanoma demonstrate significant efficacy:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBel-sar Result (Phase 2 CM)\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Control Rate (Phase 3-eligible)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e ($\\text{n}=8\/10$)\u003c\/td\u003e\n\u003ctd\u003eStandard of care (radiotherapy) leads to visual acuity of $\u0026lt;\\text{20\/200}$ in up to 87% of patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVisual Acuity Preservation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBel-sar has the potential to become the first treatment that achieves the dual goals of treating the tumor while also preserving vision.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Growth Rate Change\u003c\/td\u003e\n\u003ctd\u003eReduction from 0.351 mm\/yr to 0.011 mm\/yr among responders ($\\text{p}\u0026lt;0.0001$)\u003c\/td\u003e\n\u003ctd\u003eComplete cessation of growth following treatment among responders.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe potential for durable responses across the bladder cancer spectrum and in other solid tumors is highlighted by these findings.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 data showed that bel-sar generated $\\text{de novo}$ mature tertiary lymphoid structures (TLS) in 3\/5 participants evaluated.\u003c\/li\u003e\n\u003cli\u003e$\\text{80%}$ of the $\\text{10}$ Phase 3-eligible patients in the Phase 2 CM study were at high risk for vision loss.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Expertise in Ocular and Urologic Oncology Clinical Development\n\u003c\/h2\u003e\n\n\u003cp\u003e\nValue: Focused expertise allows for efficient trial design and execution in niche, high-unmet-need areas like choroidal melanoma and NMIBC.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\/Metric\u003c\/th\u003e\n\u003cth\u003eProgram Status\/Data Point\u003c\/th\u003e\n\u003cth\u003eAssociated Market\/Incidence\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly-Stage Choroidal Melanoma (CM)\u003c\/td\u003e\n\u003ctd\u003ePhase 3 CoMpass Trial enrollment expected to complete in \u003cstrong\u003e2026\u003c\/strong\u003e; Topline data anticipated in Q4 \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eStandard of care radiotherapy leads to vision worse than \u003cstrong\u003e20\/200\u003c\/strong\u003e in up to \u003cstrong\u003e87%\u003c\/strong\u003e of patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCM Phase 2 Efficacy (Phase 3-eligible, n=\u003cstrong\u003e10\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eTumor Control Rate: \u003cstrong\u003e80%\u003c\/strong\u003e; Visual Acuity Preservation: \u003cstrong\u003e90%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003ePrior average tumor growth rate: \u003cstrong\u003e0.351 mm\/yr\u003c\/strong\u003e; Post-treatment average growth rate: \u003cstrong\u003e0.011 mm\/yr\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Muscle Invasive Bladder Cancer (NMIBC)\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\/2 Trial data expected mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eGlobal NMIBC market expected to reach \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e by \u003cstrong\u003e2031\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcular Oncology Pipeline (Collective)\u003c\/td\u003e\n\u003ctd\u003eIncludes CM, Metastases to the Choroid (Phase 2 initiated), Cancers of the Ocular Surface (Phase 1 planned).\u003c\/td\u003e\n\u003ctd\u003eCollective annual incidence in US\/Europe: greater than \u003cstrong\u003e60,000\u003c\/strong\u003e patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position (as of Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eCash position: \u003cstrong\u003e$177.3 million\u003c\/strong\u003e; Runway into H1 \u003cstrong\u003e2027\u003c\/strong\u003e following a \u003cstrong\u003e$75 million\u003c\/strong\u003e equity financing.\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Net Loss: \u003cstrong\u003e$27.0 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nRarity: No. Many biotechs have therapeutic area expertise, but the specific combination here is less common.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Yes. Deep institutional knowledge and relationships built over years are hard for a new entrant to match.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Yes. CEO Elisabet de los Pinos emphasizes focus on execution across both ocular and urologic programs.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLeadership includes Sabine Brookman-May, MD, Senior Vice President and Therapeutic Head of Urologic Oncology.\u003c\/li\u003e\n\u003cli\u003eLeadership includes Joseph McQuaid, Executive Medical Director, heading up Clinical Development in Urology.\u003c\/li\u003e\n\u003cli\u003eThe company has secured Orphan Drug Designation from the FDA and EMA, and Fast Track designation from the FDA for early-stage choroidal melanoma.\u003c\/li\u003e\n\u003cli\u003eThe CoMpass trial operates under a Special Protocol Assessment (SPA) agreement with the FDA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary. While valuable, expertise can be hired away or diluted if the focus shifts too broadly.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Special Protocol Assessment (SPA) Agreement with the FDA for the CoMpass Trial\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The SPA provides assurance that the FDA agrees the design of the Phase 3 CoMpass trial is adequate to support a future marketing application. The trial is designed as a superiority trial comparing bel-sar versus sham control.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Endpoint\u003c\/td\u003e\n\u003ctd\u003eResult for Phase 3 Eligible Patients\u003c\/td\u003e\n\u003ctd\u003eStatistical Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVisual Acuity Preservation (12 months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e (for 9\/10 patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Control (12 months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e80% (for 8\/10 patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Growth Rate Reduction (Responders)\u003c\/td\u003e\n\u003ctd\u003eStatistically Significant Reduction\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-0.382 mm\/yr\u003c\/strong\u003e ($\\text{p} = \u0026lt;0.0001$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. Achieving an SPA, especially for a first-in-class therapy in a rare indication, is a significant de-risking event. Early-stage choroidal melanoma has no approved drugs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No. This is a formal agreement with a regulatory body that cannot be copied by a competitor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. It reflects strong regulatory strategy and successful negotiation with the FDA. Supporting operational metrics include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGlobal enrollment target of approximately \u003cstrong\u003e100\u003c\/strong\u003e patients (as of May 2024).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e240\u003c\/strong\u003e patients registered in the pre-screening tool as of Q2 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents of \u003cstrong\u003e$128.0 million\u003c\/strong\u003e as of March 31, 2025, funding operations into H2 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. It significantly reduces regulatory risk, a major barrier for competitors entering the space. The primary endpoint is time to tumor progression at \u003cstrong\u003e15\u003c\/strong\u003e months of follow-up.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAura Biosciences, Inc. (AURA) - VRIO Analysis: Management Team's Focus on Clinical Execution and Operational Improvement\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team is actively addressing operational hurdles, such as implementing measures in 2025 to improve slow enrollment in the CoMpass trial. Investigators have registered over \u003cstrong\u003e240 patients\u003c\/strong\u003e in the pre-screening tool for the CoMpass trial, highlighting global need.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No. Good management is common, but the ability to quickly pivot and improve operational metrics mid-trial is a strong sign. The CEO noted that measures implemented in 2025 led to improved enrollment in recent months following initial slower progress.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Yes. The specific culture and leadership style that drives this responsiveness are difficult to duplicate.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The consistent reporting of progress and clear guidance on data readouts show strong internal control. Guidance provided includes expected CoMpass enrollment completion in \u003cstrong\u003e2026\u003c\/strong\u003e and topline data readout in \u003cstrong\u003eQ4 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While strong, sustained advantage requires the team to convert this execution into commercial success.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Element\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eActive operational improvement measures implemented in 2025 for CoMpass trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eNo (but strong sign)\u003c\/td\u003e\n\u003ctd\u003eAbility to quickly pivot and improve operational metrics mid-trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSpecific culture and leadership style driving responsiveness.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eConsistent reporting and clear guidance on data readouts (e.g., CoMpass Q4 2027 topline).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eRequires conversion of execution into commercial success.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Operational and Financial Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCoMpass Trial Estimated Enrollment Completion: \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCoMpass Trial Topline Data Readout (15-month primary endpoint): \u003cstrong\u003eQ4 2027\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNMIBC Phase 1b\/2 Trial Data Expected: \u003cstrong\u003eMid-2026\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e\\$26.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 R\u0026amp;D Expenses: \u003cstrong\u003e\\$22.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 G\u0026amp;A Expenses: \u003cstrong\u003e\\$5.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow View Draft (Basis for Friday Submission)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis view incorporates the \u003cstrong\u003eQ3 net loss of \\$26.1 million\u003c\/strong\u003e as the primary operational cash outflow driver over the approximate 13-week period following the \u003cstrong\u003eJune 30, 2025 cash balance of \\$177.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003eTotal (13 Weeks)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$177.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e[Calculated]\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e[Calculated]\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$177.3 million\u003c\/strong\u003e (Starting Point)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Flow from Operations (Estimated Proxy)\u003c\/td\u003e\n\u003ctd\u003e[Negative Amount]\u003c\/td\u003e\n\u003ctd\u003e[Negative Amount]\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e[Negative Amount]\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-\\$26.1 million\u003c\/strong\u003e (Q3 Net Loss)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Flow from Financing (Excluding Q3 Activity)\u003c\/td\u003e\n\u003ctd\u003e[Amount\/0]\u003c\/td\u003e\n\u003ctd\u003e[Amount\/0]\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e[Amount\/0]\u003c\/td\u003e\n\u003ctd\u003e[Amount]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e[Calculated]\u003c\/td\u003e\n\u003ctd\u003e[Calculated]\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e[Calculated]\u003c\/td\u003e\n\u003ctd\u003e[Calculated, $\\approx \\$151.2M$ if no financing]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516118196373,"sku":"aura-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/aura-vrio-analysis.png?v=1740149738","url":"https:\/\/dcf-model.com\/fr\/products\/aura-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}